Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 10/20 | 1.00 |
| ▸ | THRB | P10828 | 10/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 10/20 | 1.00 |
| ▸ | BLM | P54132 | 9/20 | 1.00 |
| ▸ | RECQL | P46063 | 8/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | USP2 | O75604 | 5/20 | 1.00 |
| ▸ | HTT | P42858 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 4/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 4/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | TP53 | P04637 | 3/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL6423269 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL15159339 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL6423273 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL12864552 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL289431 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL24914323 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL18926545 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL13840952 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL22694307 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL10061862 | 1.00 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114650823-A | Pharmaceutical composition comprising FLT3 inhibitor and chemotherapeutic agent for the treatment of acute myeloid leukemia | 韩美药品株式会社 | 2022-06-21 | — | — | CN | claimed |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | HANMI PHARM. CO., LTD. (KR) | 2025-07-08 | — | — | US | disclosed |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2025-05-13 | — | — | US | disclosed |
| US-20240398755-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | IC-MedTech Corp. | 2024-12-05 | — | — | US | disclosed |
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | IC-MedTech Corp. (US) | 2024-06-04 | — | — | US | disclosed |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | IC-MedTech Corp. | 2024-05-23 | — | — | US | disclosed |
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | IC-MedTech Corp. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | Epizyme, Inc. | 2023-11-16 | — | — | US | disclosed |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | Epizyme, Inc. (US) | 2023-06-13 | — | — | US | disclosed |
| US-20220409577-A1 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | IC-MedTech Corp. | 2022-12-29 | — | — | US | disclosed |
| US-9737614-B2 | Fucoidan nanogels and methods of their use and manufacture | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2017-08-22 | — | — | US | disclosed |
| US-20160193349-A1 | FUCOIDAN NANOGELS AND METHODS OF THEIR USE AND MANUFACTURE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-07-07 | — | — | US | disclosed |
| US-20150328254-A1 | FUCOIDAN NANOGELS AND METHODS OF THEIR USE AND MANUFACTURE | MEMORIAL SLOAN KETTERING CANCER CENTER | 2015-11-19 | — | — | US | disclosed |
| US-8092828-B2 | Administering mixture of cytarabine and anthracycline | CELATOR PHARMACEUTICALS, INC. (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100303895-A1 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | CELATOR PHARMACEUTICALS, INC. | 2010-12-02 | — | — | US | disclosed |
| WO-2010133700-A1 | PHARMACEUTICAL COMPOSITION COMPRISING MICROBUBBLES FOR TARGETED TUMOR THERAPY | LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN (DE) | 2010-11-25 | — | — | WO | disclosed |
| EP-2253308-A1 | Pharmaceutical composition comprising microbubbles for targeted tumor therapy | Ludwig-Maximilians-Universität München (DE) | 2010-11-24 | — | — | EP | disclosed |
| EP-2120568-A2 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | Celator Pharmaceuticals, Inc. (US) | 2009-11-25 | — | — | EP | disclosed |
| US-20080199515-A1 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | Jazz Pharmaceuticals Therapeutics, Inc. | 2008-08-21 | — | — | US | disclosed |
| WO-2008101214-A2 | FIXED DRUG RATIOS FOR TREATMENT OF HEMATOPOIETIC CANCERS AND PROLIFERATIVE DISORDERS | CELATOR PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230364086-A1 | COMBINATION THERAPIES WITH EHMT2 INHIBITORS | EHMT2, BHMT, SHMT2 | TOP2A 199/4885MEN1 1229/4885THRB 916/4885 |
| US-11872233-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | TOP2A 2184/4885MEN1 2407/4885THRB 3967/4885 |
| US-12350265-B2 | Pharmaceutical composition for treating acute myeloid leukemia, containing FLT3 inhibitor and chemotherapeutic agents | FLT3, MCL1, CSF3R | TOP2A 2835/4885MEN1 1801/4885THRB 2992/4885 |
| US-20220409577-A1 | INTRATUMORAL ADMINISTRATION OF ASCORBIC ACID AND QUINONE COMPOUNDS FOR TUMOR TREATMENT | NDUFB7, NDUFA12, NDUFB11 | TOP2A 859/4885MEN1 1050/4885THRB 2730/4885 |
| US-20240165084-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | NQO1, ADH7, CYP27B1 | TOP2A 2184/4885MEN1 2407/4885THRB 3967/4885 |
| US-11998523-B2 | Ascorbic acid and quinone compounds for treating Chagas disease | NQO1, ADH7, TALDO1 | TOP2A 2041/4885MEN1 2264/4885THRB 3280/4885 |
| US-12295957-B2 | Ascorbic acid and quinone compounds in combination with an antiparasitic agent for treating a parasitic disease | NQO1, ADH7, CYP27B1 | TOP2A 2184/4885MEN1 2407/4885THRB 3967/4885 |
| US-11672800-B2 | Combination therapies with EHMT2 inhibitors | EHMT2, BHMT, SHMT2 | TOP2A 199/4885MEN1 1229/4885THRB 916/4885 |
| US-20240398755-A1 | ASCORBIC ACID AND QUINONE COMPOUNDS FOR TREATING CHAGAS DISEASE | NQO1, ADH7, TALDO1 | TOP2A 2041/4885MEN1 2264/4885THRB 3280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.